AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Repatha	Page:	1 of 5
Effective Date:	8/17/2023	Last Review Date:	6/6/2023

Applies to:	☒Illinois	☐Florida	☒Florida Kids
	☐New Jersey	☒Maryland	☐Michigan
	☒Pennsylvania Kids	☐Virginia	☐Arizona

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Repatha under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

A. Repatha is indicated in adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization.
B. Repatha is indicated as an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.
C. Repatha is indicated as an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C.
D. Repatha is indicated as an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C.

All other indications are considered experimental/investigational and not medically necessary.

Applicable Drug List:

Repatha

Policy/Guideline:

Documentation:
Submission of the following information is necessary to initiate the prior authorization review:

A. Current LDL-C level for both initial requests and continuation requests. The level must be dated within the six months preceding the authorization request.
B. Untreated (before any lipid-lowering therapy) LDL-C level if requesting Repatha to treat primary hyperlipidemia, heterozygous or homozygous familial hypercholesterolemia.

C. Chart notes confirming clinical atherosclerotic cardiovascular disease (ASCVD) if requesting Repatha to treat clinical ASCVD (see Appendix A).
D. If member has contraindication or intolerance to statins, chart notes confirming the contraindication or intolerance (see Appendices B and C).

Criteria for Initial Approval:

A. Clinical atherosclerotic cardiovascular disease (ASCVD)

Authorization of 6 months may be granted for treatment of clinical atherosclerotic cardiovascular disease when both of the following criteria are met:

1. Member has a history of clinical ASCVD (see Appendix A).
2. Member meets at least one of the following criteria:
   i. Member has a current LDL-C level ≥ 70 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
   ii. Member has a current LDL-C level ≥ 70 mg/dL with contraindication or intolerance to statins (see Appendices B and C).

B. Primary hyperlipidemia

Authorization of 6 months may be granted for treatment of primary hyperlipidemia when both of the following criteria are met:

1. Member had an untreated (before any lipid-lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
2. Member meets at least one of the following criteria:
   i. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
   ii. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (see Appendices B and C).

C. Heterozygous familial hypercholesterolemia (HeFH)

Authorization of 6 months may be granted for treatment of heterozygous familial hypercholesterolemia when both of the following criteria are met:

1. Member meets either of the following criteria:
   i. Member is 18 years of age or older and had an untreated (before any lipid-lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
   ii. Member is less than 18 years of age and had an untreated (before any lipid-lowering therapy) LDL-C level ≥ 160 mg/dL in the absence of a secondary cause.

2. Member meets at least one of the following criteria:
   i. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
   ii. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (see Appendices B and C).

D. Homozygous familial hypercholesterolemia (HoFH)

Authorization of 6 months may be granted for treatment of homozygous familial hypercholesterolemia when both of the following criteria are met:

1. Member meets either of the following criteria:
   i. Member is 18 years of age or older and had an untreated (before any lipid-lowering therapy) LDL-C level ≥ 190 mg/dL in the absence of a secondary cause.
   ii. Member is less than 18 years of age and had an untreated (before any lipid-lowering therapy) LDL-C level ≥ 160 mg/dL in the absence of a secondary cause.
2. Member meets at least one of the following criteria:
   i. Member has a current LDL-C level ≥ 100 mg/dL after at least three months of treatment with a high-intensity statin dose in combination with ezetimibe. If the member is unable to tolerate a high-intensity statin dose, a moderate-intensity statin dose may be used.
   ii. Member has a current LDL-C level ≥ 100 mg/dL with a contraindication or intolerance to statins (see Appendices B and C).

Continuation of Therapy:

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in criteria for initial approval who achieve or maintain an LDL-C reduction (e.g., LDL-C is now at goal, robust lowering of LDL-C).

Appendix:

APPENDIX A. Clinical ASCVD

- Acute coronary syndromes
- Myocardial infarction
- Stable or unstable angina
- Coronary or other arterial revascularization procedure (e.g., percutaneous coronary intervention [PCI], coronary artery bypass graft [CABG] surgery)
- Stroke of presumed atherosclerotic origin
- Transient ischemic attack (TIA)

- Non-cardiac peripheral arterial disease (PAD) of presumed atherosclerotic origin (e.g., carotid artery stenosis, lower extremity PAD)
- Obstructive coronary artery disease (defined as fifty percent or greater stenosis on cardiac computed tomography angiogram or catheterization)
- Coronary Artery Calcium (CAC) Score ≥ 1000

APPENDIX B. Statin-associated muscle symptoms (SAMS) and statin re-challenge

- Score of 7 or higher on the Statin-Associated Muscle Symptom Clinical Index (SAMS-CI)
- Statin-associated elevation in creatine kinase (CK) level ≥ 10 times upper limit of normal (ULN)
  NOTE: Statin re-challenge is NOT required for members who have experienced an elevation of CK level ≥10 times ULN after receiving lipid-lowering therapy (LLT) with a statin.

APPENDIX C. Contraindications to statins

- Active liver disease, including unexplained persistent elevations in hepatic transaminase levels (e.g., alanine transaminase (ALT) level ≥ 3 times ULN)
- Pregnancy or planned pregnancy
- Breastfeeding

Approval Duration and Quantity Restrictions:

Approval:

- Initials: 6 months; Renewals: 12 months

Quantity Level Limit:

- Repatha 140 mg syringe or SureClick autoinjector: 3 syringes/ SureClick per 28 days
- Repatha 420 mg Pushtronex system: 1 injection per 28 days

References:

1. Repatha [package insert]. Thousand Oaks, CA: Amgen, Inc.; September 2021.
2. Lloyd-Jones DM, Morris PB, Ballantybe CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee [published correction appears in J Am Coll Cardiol. 2023 Jan 3;81(1):104]. *J Am Coll Cardiol*. 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006
3. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*. 2015;372(25):2387-2397. doi:10.1056/NEJMoa1410489
4. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 — full report. *J Clin Lipidol*. 2015;9:(2)129–169. doi:10.1016/j.jacl.2015.02.003

5. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. [published correction appears in Eur Heart J. 2020 Dec 14;41(47):4517]. *Eur Heart J*. 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273
6. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *Eur Heart J*. 2014;35(32):2146-2157. doi:10.1093/eurheartj/ehu274
7. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015;385(9965):341-350. doi:10.1016/S0140-6736(14)61374-X
8. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2015;11(1):1-23. doi:10.5114/aoms.2015.49807
9. Sabatine MC, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
10. Hulten EA, Carbonaro S, Petrillo SP, et al. Prognostic value of cardiac computed tomography angiography. *J Am Coll Cardiol.* 2011;57(10):1237-1247. doi:10.1016/j.jacc.2010.10.011
11. Min JK, Labounty TM, Gomez MJ, et al. Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. *Atherosclerosis.* 2014;232(2):298-304. doi:10.1016/j.atherosclerosis.2013.09.025
12. Robinson, JG, Rogers WJ, Nedergaard BS, et al. Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. *Clin Cardiol*, 2014;37(4):195-203. doi:10.1002/clc.22252
13. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. *J Intern Med*. 2009 May;265(5):568-80.
14. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol: report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018.
15. Beavers CJ, Kelly MS. Dyslipidemia.In: Murphy Je, Lee MW,eds. Pharmacotherapy Self-Assessment Program, 2019 Book 1. Cardiology. Lenexa, KS: American College of Clinical Pharmacy, 2019:41-42.
16. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. 2019; 8(24):e013225. DOI: 10.1161/JAHA119.013225.